Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Comprehensive Genomic Profiling of Malignant Effusions in Patients with Metastatic Lung Adenocarcinoma.

Yang SR, Lin CY, Stehr H, Long SR, Kong CS, Berry GJ, Zehnder JL, Kunder CA.

J Mol Diagn. 2018 Mar;20(2):184-194. doi: 10.1016/j.jmoldx.2017.10.007. Epub 2017 Dec 19.

PMID:
29269277
2.

Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.

Drilon A, Wang L, Arcila ME, Balasubramanian S, Greenbowe JR, Ross JS, Stephens P, Lipson D, Miller VA, Kris MG, Ladanyi M, Rizvi NA.

Clin Cancer Res. 2015 Aug 15;21(16):3631-9. doi: 10.1158/1078-0432.CCR-14-2683. Epub 2015 Jan 7.

3.

Next-generation sequencing of non-small cell lung cancer using a customized, targeted sequencing panel: Emphasis on small biopsy and cytology.

DiBardino DM, Rawson DW, Saqi A, Heymann JJ, Pagan CA, Bulman WA.

Cytojournal. 2017 Mar 20;14:7. doi: 10.4103/1742-6413.202602. eCollection 2017.

4.

Next generation sequencing-based molecular profiling of lung adenocarcinoma using pleural effusion specimens.

Liu L, Shao D, Deng Q, Tang H, Wang J, Liu J, Guo F, Lin Y, Peng Z, Mao M, Kristiansen K, Ye M, He J.

J Thorac Dis. 2018 May;10(5):2631-2637. doi: 10.21037/jtd.2018.04.125.

5.

Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.

Rozenblum AB, Ilouze M, Dudnik E, Dvir A, Soussan-Gutman L, Geva S, Peled N.

J Thorac Oncol. 2017 Feb;12(2):258-268. doi: 10.1016/j.jtho.2016.10.021. Epub 2016 Nov 16.

6.

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.

Zugazagoitia J, Ramos I, Trigo JM, Palka M, Gómez-Rueda A, Jantus-Lewintre E, Camps C, Isla D, Iranzo P, Ponce-Aix S, García-Campelo R, Provencio M, Franco F, Bernabé R, Juan-Vidal O, Felip E, de Castro J, Sanchez-Torres JM, Faul I, Lanman RB, Garrido P, Paz-Ares L.

Ann Oncol. 2019 Feb 1;30(2):290-296. doi: 10.1093/annonc/mdy512.

PMID:
30535340
7.

FNA smears as a potential source of DNA for targeted next-generation sequencing of lung adenocarcinomas.

Treece AL, Montgomery ND, Patel NM, Civalier CJ, Dodd LG, Gulley ML, Booker JK, Weck KE.

Cancer Cytopathol. 2016 Jun;124(6):406-14. doi: 10.1002/cncy.21699. Epub 2016 Feb 16.

8.

Accuracy of next-generation sequencing for the identification of clinically relevant variants in cytology smears in lung adenocarcinoma.

Baum JE, Zhang P, Hoda RS, Geraghty B, Rennert H, Narula N, Fernandes HD.

Cancer Cytopathol. 2017 Jun;125(6):398-406. doi: 10.1002/cncy.21844. Epub 2017 Mar 8.

9.

Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.

Paweletz CP, Sacher AG, Raymond CK, Alden RS, O'Connell A, Mach SL, Kuang Y, Gandhi L, Kirschmeier P, English JM, Lim LP, Jänne PA, Oxnard GR.

Clin Cancer Res. 2016 Feb 15;22(4):915-22. doi: 10.1158/1078-0432.CCR-15-1627-T. Epub 2015 Oct 12.

10.

Targeted next-generation sequencing using fine-needle aspirates from adenocarcinomas of the lung.

Karnes HE, Duncavage EJ, Bernadt CT.

Cancer Cytopathol. 2014 Feb;122(2):104-13. doi: 10.1002/cncy.21361. Epub 2013 Nov 12.

11.

Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.

Cani AK, Hovelson DH, Demirci H, Johnson MW, Tomlins SA, Rao RC.

Oncotarget. 2017 Jan 31;8(5):7989-7998. doi: 10.18632/oncotarget.14008.

12.

Concurrent fine needle aspirations and core needle biopsies: a comparative study of substrates for next-generation sequencing in solid organ malignancies.

Roy-Chowdhuri S, Chen H, Singh RR, Krishnamurthy S, Patel KP, Routbort MJ, Manekia J, Barkoh BA, Yao H, Sabir S, Broaddus RR, Medeiros LJ, Staerkel G, Stewart J, Luthra R.

Mod Pathol. 2017 Apr;30(4):499-508. doi: 10.1038/modpathol.2016.228. Epub 2017 Jan 13.

13.

Cytology smears as excellent starting material for next-generation sequencing-based molecular testing of patients with adenocarcinoma of the lung.

Velizheva NP, Rechsteiner MP, Wong CE, Zhong Q, Rössle M, Bode B, Moch H, Soltermann A, Wild PJ, Tischler V.

Cancer Cytopathol. 2017 Jan;125(1):30-40. doi: 10.1002/cncy.21771. Epub 2016 Sep 16.

14.

Lung cancer adrenal gland metastasis: Optimal fine-needle aspirate and touch preparation smear cellularity characteristics for successful theranostic next-generation sequencing.

Gleeson FC, Kipp BR, Levy MJ, Voss JS, Campion MB, Minot DM, Tu ZJ, Klee EW, Lazaridis KN, Kerr SE.

Cancer Cytopathol. 2014 Nov;122(11):822-32. doi: 10.1002/cncy.21464. Epub 2014 Jul 15.

15.

Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.

DiBardino DM, Saqi A, Elvin JA, Greenbowe J, Suh JH, Miller VA, Ali SM, Stoopler M, Bulman WA.

Clin Lung Cancer. 2016 Nov;17(6):517-522.e3. doi: 10.1016/j.cllc.2016.05.017. Epub 2016 Jun 8.

PMID:
27378171
16.

Using "residual" FNA rinse and body fluid specimens for next-generation sequencing: An institutional experience.

Wei S, Lieberman D, Morrissette JJ, Baloch ZW, Roth DB, McGrath C.

Cancer Cytopathol. 2016 May;124(5):324-9. doi: 10.1002/cncy.21666. Epub 2015 Dec 18.

17.

Clinical Application of Picodroplet Digital PCR Technology for Rapid Detection of EGFR T790M in Next-Generation Sequencing Libraries and DNA from Limited Tumor Samples.

Borsu L, Intrieri J, Thampi L, Yu H, Riely G, Nafa K, Chandramohan R, Ladanyi M, Arcila ME.

J Mol Diagn. 2016 Nov;18(6):903-911. doi: 10.1016/j.jmoldx.2016.07.004. Epub 2016 Sep 12.

18.

Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.

Wen S, Dai L, Wang L, Wang W, Wu D, Wang K, He Z, Wang A, Chen H, Zhang P, Dong X, Dong YA, Wang K, Yao M, Wang M.

Oncologist. 2019 Mar 22. pii: theoncologist.2018-0572. doi: 10.1634/theoncologist.2018-0572. [Epub ahead of print]

PMID:
30902917
19.

Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.

Suh JH, Johnson A, Albacker L, Wang K, Chmielecki J, Frampton G, Gay L, Elvin JA, Vergilio JA, Ali S, Miller VA, Stephens PJ, Ross JS.

Oncologist. 2016 Jun;21(6):684-91. doi: 10.1634/theoncologist.2016-0030. Epub 2016 May 5.

20.

Molecular Profiling of Malignant Pleural Effusion in Metastatic Non-Small-Cell Lung Carcinoma. The Effect of Preanalytical Factors.

Carter J, Miller JA, Feller-Kopman D, Ettinger D, Sidransky D, Maleki Z.

Ann Am Thorac Soc. 2017 Jul;14(7):1169-1176. doi: 10.1513/AnnalsATS.201609-709OC.

PMID:
28557526

Supplemental Content

Support Center